



## Hunter Capital RTO 1 AB (publ) provides an update on the planned transaction with ResoTher Pharma A/S

Hunter Capital RTO 1 AB (publ) (the "**Company**") today provides an update on the previously announced Letter of Intent ("**LOI**") regarding the planned reverse takeover ("**RTO**") of the Danish biotechnology company ResoTher Pharma A/S ("**ResoTher Pharma**").

ResoTher Pharma has successfully completed a bridge financing of approximately SEK 14.8 million, marking an important milestone in its financing strategy ahead of the larger pre-RTO financing round planned for September 2026. The bridge financing was completed at a pre-money valuation of approximately SEK 225 million (DKK 157.5 million).

The completed bridge financing forms part of the financing strategy supporting the proposed RTO transaction and the larger financing round expected to be completed in connection with the proposed listing.

In connection with the bridge financing, ResoTher Pharma has also reported continued progress in the clinical development of its lead drug candidate, RTP-026. ResoTher Pharma is currently completing a placebo-controlled, double-blinded Phase 2a study evaluating RTP-026 as a potential first-in-class cardioprotective treatment for patients suffering an acute ST-elevation myocardial infarction (STEMI).

ResoTher Pharma has announced that:

- enrolment of all 65 patients in the Phase 2a study was completed in April;
- a subsequent review of blinded Phase 2a data indicates that RTP-026 continues to demonstrate a strong safety profile in the studied high-risk patient population;
- no fatal cases or rehospitalisations due to major adverse cardiovascular events have been observed in the study;
- preliminary blinded imaging data indicate a potential protective effect on heart tissue following reperfusion therapy (PCI);
- RTP-026 drug exposure levels have been shown to be well within the expected therapeutic range; and
- the unblinded Phase 2a study results are expected to be available in September 2026.

The successful bridge financing and the reported clinical progress represent important milestones in ResoTher Pharma's continued development and preparations for the planned main financing round.

The parties continue to work towards completion of the planned transaction in accordance with the LOI, including customary due diligence, preparation of definitive transaction agreements, Spotlight Stock Market's review and other activities required to complete the planned transaction.

The Company will continue to keep the market informed of any material developments as the transaction process progresses.

Completion of the proposed transaction remains subject to, among other things, the execution of definitive agreements, positive unblinded Phase 2a safety results, completion of customary due diligence, receipt of all necessary corporate and regulatory approvals, and other customary closing conditions.

**For further information, please contact:**

Jacob Eriksson, CEO

Email: [jacob.eriksson@hunterto.se](mailto:jacob.eriksson@hunterto.se)

Website: [www.hunterto.se](http://www.hunterto.se)